Supercharged immune cells take on Hard-to-Treat blood cancers
NCT ID NCT07509086
First seen Apr 07, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This study tests a new type of CAR-T cell therapy, boosted with a protein called IL-15, in people with multiple myeloma or plasma cell leukemia that has come back or not responded to treatment. The goal is to see if these enhanced immune cells can shrink or eliminate the cancer. About 25 adults aged 18 to 80 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.